Second-line treatment of advanced gastric cancer with oxaliplatin plus raltitrexed

Onkologie

Volumn 26, Issue 3, 2003, Pages 255-258

  Schmid, K E ^b   Kornek, G V ^b   Schull B ^b   Raderer, M ^b   Lenauer, A ^b   Depisch, D ^b   Lang, F ^b   Scheithauer, Werner ^a  

^a MEDICAL UNIVERSITY OF VIENNA   (Austria)

^b NONE

Author keywords

Advanced gastric cancer; Oxaliplatin; Raltitrexed; Second line treatment

Indexed keywords

DEXAMETHASONE; ONDANSETRON; OXALIPLATIN; RALTITREXED;

ADULT; ADVERSE DRUG REACTION; AGED; ALOPECIA; ANEMIA; ANTINEOPLASTIC ACTIVITY; ARTICLE; ASTHENIA; BLOOD TOXICITY; CANCER CHEMOTHERAPY; CANCER COMBINATION CHEMOTHERAPY; CANCER GROWTH; CANCER PALLIATIVE THERAPY; CANCER SURVIVAL; CHEMOTHERAPY INDUCED EMESIS; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIARRHEA; DRUG EFFECT; DRUG EFFICACY; DRUG TOXICITY; FEMALE; HUMAN; INFECTION; LEUKOPENIA; LIVER FUNCTION TEST; MALE; METASTASIS; NAUSEA; NEUROTOXICITY; NEUTROPENIA; PAIN; PARESTHESIA; PERIPHERAL NEUROPATHY; SALVAGE THERAPY; STOMACH CANCER; THROMBOCYTOPENIA; TREATMENT FAILURE; TREATMENT OUTCOME;

ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; DISEASE PROGRESSION; DISEASE-FREE SURVIVAL; FEMALE; HUMANS; MALE; MIDDLE AGED; NEOPLASM STAGING; ORGANOPLATINUM COMPOUNDS; PALLIATIVE CARE; QUINAZOLINES; RETREATMENT; SALVAGE THERAPY; STOMACH NEOPLASMS; SURVIVAL RATE; THIOPHENES;

EID: 0038004543     PISSN: 0378584X     EISSN: None     Source Type: Journal    
DOI: 10.1159/000071621     Document Type: Article

References (16)

1. Janunger KG, Hafstrom L, Nygren P, Glimelius B: A systematic overview of chemotherapy effects in gastric cancer. Acta Oncol 2001;40:309-326.
2. De Vivo R, Pignata S, Palaia R, Parisi V, Daniele B: The role of chemotherapy in the management of gastric cancer. J Clin Gastroenterol 2000;30:364-371.
3. Hartung G, Hofheinz R, Buchheidt D, Rost A, Brecht A, Forche K, Schroder M, Wojatschek C, Fritze D, Hehlmann R, Queisser W: Combination of bolus 5-fluorouracil, folinic acid and mitomycin C in advanced gastric cancer: Results of a phase II trial. Onkologie 2000;23:444-447.
4. Hill ME, Cunningham D: Medical management of advanced gastric cancer. Cancer Treat Rev 1998;24:113-118.
5. Raymond E, Djelloul S, Buquet-Fagot C, Goldwasser F, Mester J, Cvitkovic E, Louvet C: Oxaliplatin (l-OHP) and cisplatin (CDDP) in combination with 5-FU, specific thymidilate synthase (TS) inhibitors (AG337, ZD1694), and topoisomerase I (TOPO-I) inhibitors (SN38, CPT-11) in human colonic, ovarian and breast cancers. Proc Am Assoc Cancer Res 1996;37:291 (abstr 1981).
6. Scheithauer W, Kornek GV, Ulrich-Pur H, Penz M, Raderer M, Salek T, Haider K, Kwasny W, Depisch D: Oxaliplatin plus raltitrexed in patients with advanced colorectal carcinoma. Results of a phase I-II trial. Cancer 2001;91:1264-1271.
7. Fizazi K, Ducreux M, Ruffie P, Bonnay M, Daniel C, Soria JC: Phase-I, dose-finding, and pharmacokinetic study of raltitrexed combined with oxaliplatin in patients with advanced cancer. J Clin Oncol 2000;18:2293-2300.
8. Douillard JY, Michel P, Gamelin E, Conroy E, Francois E, Raoul JL, Becouarn Y, Bertheault F, Cvitkovic E, Nasca S, Ychou M, Fandi A, Seitz JF: Raltitrexed ('Tomudex') plus oxaliplatin: An active combination for first-line chemotherapy in patients with metastatic colorectal cancer. Proc Am Soc Clin Oncol 2000;19:250a (abstr 971).
9. Cascinu S, Graziano F, Ferrau F, Catalano V, Massacesi C, Santini D, Silva RR, Barni S, Zaniboni A, Battelli N, Siena S, Giordani P, Mari D, Balzelli AM, Antognoli S, Malsano R, Priolo D, Pessi MA, Tonini G, Rota S, La bianca R: Raltitrexed plus oxaliplatin (TOMOX) as first-line chemotherapy for metastatic colorectal cancer. A phase II study of the Italian Group for the Study of Gastrointestinal Tract Carcinomas (GISCAD). Ann Oncol 2002;13:716-720.
10. Scheithauer W, Kornek GV, Schuell B, Ulrich-Pur H, Penz M, Raderer M, Lang F, Schneeweiss B, Lenauer A, Depisch D: Second-line treatment with oxaliplatin + raltitrexed in patients with advanced colorectal cancer failing fluoropyrimidine / leucovorin-based chemotherapy. Ann Oncol 2001;12:709-714.
11. Maisano R, Caristi N, Toscano G, Aragona M, Spadaro P, Mare M, Zavattieri M, La Torre F: Oxaliplatin and raltitrexed in the treatment of inoperable malignant pleural mesothelioma: Results of a pilot study. Tumori 2001;87:391-393.
12. Van Cutsem E, Cunningham D, Maroun J, Cervantes A, Glimelius B: Raltitrexed: Current clinical status and future directions. Ann Oncol 2002;13:513-522.
13. Catalano V, Graziano F, Salvagni S, Ferrau F, Poletti P, Maisano R, Pucci F, Baldelli AM, Labianca R, Lai V, Catalano G, Cascinu S: Lack of resistance to oxaliplatin (L-OHP)-based chemotherapy in patients (pts) with advanced gastric cancer previously treated with cisplatin-containing regimens: Preliminary results of a phase II study. Proc Am Soc Clin Oncol 2002;21:97b (abstr 2200).
14. Miller AB, Hoogstraten B, Staquet M, Winkler V: Reporting results of cancer treatment. Cancer 1981;47:207-214.
15. Gehan EA: The determination of the number of patients required in a follow-up trial of a new chemotherapeutic agent. J Chron Dis 1961;13:346-353.
16. Culy CR, Clemett D, Wiseman LR: Oxaliplatin. A review of its pharmacological properties and clinical efficacy in metastatic colorectal cancer and its potential in other malignancies. Drugs 2000;60:895-924.